These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29998951)

  • 1. [Preclinical and clinical properties of Bezlotoxumab (ZINPLAVA
    Kinoshita K
    Nihon Yakurigaku Zasshi; 2018; 152(1):39-50. PubMed ID: 29998951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment?
    Posteraro B; Pea F; Masucci L; Posteraro P; Sanguinetti M
    Expert Opin Biol Ther; 2018 Apr; 18(4):469-476. PubMed ID: 29534621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
    Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
    J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
    Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
    Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
    Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.
    Hernandez LD; Racine F; Xiao L; DiNunzio E; Hairston N; Sheth PR; Murgolo NJ; Therien AG
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1052-60. PubMed ID: 25451052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.
    Villafuerte Gálvez JA; Kelly CP
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):611-622. PubMed ID: 28636484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
    Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
    Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection.
    Birch T; Golan Y; Rizzardini G; Jensen E; Gabryelski L; Guris D; Dorr MB
    J Antimicrob Chemother; 2018 Sep; 73(9):2524-2528. PubMed ID: 29788418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bezlotoxumab for the Prevention of
    Chahine EB; Cho JC; Worley MV
    Consult Pharm; 2018 Feb; 33(2):89-97. PubMed ID: 29409575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
    Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
    Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model.
    Qiu H; Cassan R; Johnstone D; Han X; Joyee AG; McQuoid M; Masi A; Merluza J; Hrehorak B; Reid R; Kennedy K; Tighe B; Rak C; Leonhardt M; Dupas B; Saward L; Berry JD; Nykiforuk CL
    PLoS One; 2016; 11(6):e0157970. PubMed ID: 27336843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
    Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG
    J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Association Reveals Protection against Recurrence of
    Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
    mSphere; 2020 May; 5(3):. PubMed ID: 32376702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN; Kelly CP; Rahav G; Lee C; Dubberke ER; Kumar PN; Yacyshyn B; Kao D; Eves K; Ellison MC; Hanson ME; Guris D; Dorr MB
    Clin Infect Dis; 2018 Aug; 67(5):649-656. PubMed ID: 29538686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
    Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
    Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2017 Jul; 53(7):385-392. PubMed ID: 28837182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
    Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
    Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.